Clinical Trial Update: Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Palazestrant in combination with ribociclib as first-line therapy for ER+/HER2- advanced/metastatic breast cancer; recruitment is ongoi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Palazestrant (palazestrant)
• Ribociclib (ribociclib)

Snippet

Sponsor: Olema Pharmaceuticals, Inc. | Conditions: Breast Cancer, Locally Advanced Breast Cancer | Phase 3 | Status: RECRUITING